Maternal RSV Vaccine Cuts Infant Hospitalizations by 72 Percent: Study Finds
Vaccinating pregnant women against respiratory syncytial virus (RSV) has led to a significant drop in newborn hospital admissions for severe lung infections, according to a new study published in The Lancet Child and Adolescent Health.
RSV is a widespread virus that typically causes mild cold-like symptoms but can lead to serious conditions such as bronchiolitis in infants. It remains the leading infectious cause of baby hospitalisations in the UK and globally. Protection during early infancy is critical, especially as RSV can result in intensive care admissions for the youngest patients.
The research assessed the real-world effectiveness of the RSV vaccine during pregnancy. The team studied 537 babies admitted to hospitals across England and Scotland during the 2024-2025 RSV season. Of these, 391 tested positive for RSV. The analysis revealed that mothers of RSV-negative babies were more than twice as likely to have received the vaccine before delivery compared to mothers of RSV-positive babies 41% versus 19%.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.